Usui Keisuke, Saito Anneyuko I
Department of Radiation Oncology, Faculty of Medicine, Juntendo University, Tokyo 113-8421, Japan.
Department of Radiological Technology, Faculty of Health Science, Juntendo University, Tokyo 113-8421, Japan.
Mol Clin Oncol. 2024 Jul 24;21(4):68. doi: 10.3892/mco.2024.2766. eCollection 2024 Oct.
The treatment outcomes of patients with unresectable rectal cancer are complex, and concurrent chemoradiation therapy is the main treatment option. Radiosensitizers can enhance the effect of localized intratumoral hypoxia, contributing to local control and symptomatic relief. The present study evaluated the feasibility and safety of radiosensitization using hydrogen peroxide combined with radiation therapy (RT) in patients with unresectable rectal cancer. A total of 13 patients with rectal cancer were recruited in the present study. Radiosensitization was performed twice weekly in combination with RT. Gauze soaked in 3% hydrogen peroxide solution was inserted into the anus, ensuring firm contact with the lesion. In total, 45-65 Gy was delivered in 25-33 fractions to the whole pelvis from four directions using 10 MV X-rays 5 days per week. Acute and late adverse events were evaluated 1 and 6 months after the completion of RT. Treatment was well tolerated, with no acute grade 3 or worse events noted, and no patient developed rectal fistula, necrosis, obstruction, perforation, stenosis, ulcer or retroperitoneal hemorrhage. No notable late adverse events, beyond 6 months, were observed at the end of the analysis. All patients experienced pain relief, hemostatic effects and tumor shrinkage. Therefore, the use of a hydrogen peroxide solution-soaked gauze in the rectum may be a promising option for patients with inoperable rectal tumors. The limitations of the present study are that the patient population was small and the observation time was relatively short. This study was retrospectively registered with the University Hospital Medical Information Network Center (trial registration no. R000061902) on April 21, 2024.
不可切除直肠癌患者的治疗结果较为复杂,同步放化疗是主要的治疗选择。放射增敏剂可增强局部肿瘤内缺氧的影响,有助于局部控制和症状缓解。本研究评估了过氧化氢联合放疗(RT)对不可切除直肠癌患者进行放射增敏的可行性和安全性。本研究共招募了13例直肠癌患者。放射增敏每周进行两次并联合放疗。将浸泡在3%过氧化氢溶液中的纱布插入肛门,确保与病变紧密接触。每周5天,使用10 MV X射线从四个方向对整个盆腔进行放疗,共25 - 33次分割,总剂量为45 - 65 Gy。在放疗结束后1个月和6个月评估急性和晚期不良事件。治疗耐受性良好,未观察到急性3级或更严重的事件,也没有患者出现直肠瘘、坏死、梗阻、穿孔、狭窄、溃疡或腹膜后出血。在分析结束时,未观察到超过6个月的明显晚期不良事件。所有患者均出现疼痛缓解、止血效果和肿瘤缩小。因此,对于无法手术的直肠肿瘤患者,直肠内使用过氧化氢溶液浸泡的纱布可能是一种有前景的选择。本研究的局限性在于患者数量较少且观察时间相对较短。本研究于2024年4月21日在大学医院医学信息网络中心进行回顾性注册(试验注册号:R000061902)。